Hiperuricemia, enfermedad renal crónica y trasplante renal (parte II)
Resumen
La hiperuricemia (HU) en el trasplante renal (TR) ha sido definida igual que en la población general en las Guías KDIGO como valores por encima de 6 mg/dl en mujeres y 7 mg/dl en hombres. La incidencia de HU en algunas poblaciones es de 28%1, alcanzando el 80% en la era Ciclosporina (CSA)2. La HU se observa precozmente luego del TR, los factores de riesgo asociados con su desarrollo incluyen: edad avanzada al momento del TR; historia de gota o HU pre-existente; obesidad; presencia de síndrome metabólico (SM); deterioro de la función del injerto; uso de inmunosupresores, principalmente ciclosporina (CSA); uso de diuréticos.
Citas
Sullivan PM, William A, Tichy EM.Hyperuricemia and gout in solid-organ transplant: update in pharmacological management. Prog Transplant. 2015;25(3):263-70.
Mazali FC, Mazzali M. Uric acid and transplantation. Semin Nephrol. 2011 Sep;31(5):466-71.
Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383-91.
Hart A, Jackson S, Kasiske BL, Mauer MS, Najafian B, Matas AJ, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. Transplantation. 2014;97(10):1066-71.
Weng SC, Shu KH, Tarng DC, Cheng CH, Chen CH, Yu TM, et al. Uric acid is highly associated with kidney allograft survival in a time-varying analysis. Transplant Proc. 2014;46(2): 505-10.
Einollahi B, Einollahi H, Nafar M, Rostami Z. Prevalence and risk factors of hyperuricemia among kidney transplant recipients. Indian J Nephrol. 2013;23(3):201-5.
Malheiro J, Almeida M, Fonseca I, Martins LS, Pedroso S, Dias L, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Transplant Proc. 2012 ;44(8):2369-72.
Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5): 974-9.
Better OS. Tubular dysfunction following kidney transplantation. Nephron. 1980;25(5):209-13.
Marcén R, Gallego N, Orofino L, Gámez C, Estepa MR, Sabater J, et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron. 1995;70(3):307-13.
Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron. 1998;80(4):450-7.
Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990;10(4):296-309.
Chapman JR, Griffiths D, Harding NG, Morris PJ. Reversibility of cyclosporin nephrotoxicity after three months’ treatment. Lancet. 1985;1(8421):128-30.
Numakura K, Satoh S, Tsuchiya N, Saito M, Maita S, Obara T, et al. Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. Transplantation. 2012;94(2):145-51.
Ochiai T, Ishibashi M, Fukao K, Takahashi K, Endo T, Yokoyama I, et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. Transplant Proc. 1995;27(1):50-3.
Charpentier B, Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, et al Sirolimus European Renal Transplant Study Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Transplant Proc. 2003;35(3 Suppl):58S-61S.
Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, et al. Sirolimus European Renal Transplant Study Group Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002;2(5):436-42.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6) :F991-7.
Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation. 1991;52(1):64-7.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-6.
Kim SM, Choi YW, Seok HY, Jeong KH, Lee SH, Lee TW, et al. Reducing serum uric acid attenuates TGF-beta1-induced profibrogenic progression in type 2 diabetic nephropathy. Nephron Exp Nephrol. 2012;121(3-4):e109-21.
Webb R, Jeffries M, Sawalha AH. Uric acid directly promotes human T-cell activation. Am J Medical Sciences. 2009 ;337(1):23-7.
Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988;156(5):397-400.
Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86(5):652-8.
Oliveras A. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant. 2003;17(1):1-8.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885-92.
Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999;33(2):225-34.
Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-90.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170-80.
Duran M, Murat SN, Ornek E. Does Serum Uric Acid Level Affect Coronary Collaterals in Patients With Acute Coronary Syndrome? Angiology. 2013;64(4):325-6.
Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041-9.
Johnson RJ, Sánchez-Lozada LG, Mazzali M, Feig DI, Kanbay M, Sautin YY. What are the key arguments against uric acid as a true risk factor for hypertension? Hypertension. 2013;61(5):948-51.
Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35(3):746-51.
Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebocontrolled studies. Circulation. 2002;105(22):2619-24.
Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858-65.
Mustard JF, Murphy EA, Ogryzlo MA, Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J. 1963;89:1207-11.
Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32(6):712-20.
Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol. 2009;103(6):867-71.
Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796-803.
Chung BH, Kang SH, Hwang HS, Choi BS, Park CW, Kim YS, et al. Clinical significance of earlyonset hyperuricemia in renal transplant recipients. Nephron Clin Pract. 2011;117(3):c276-83.
Caliskan Y, Gorgulu N, Yelken B, Akturk F, Yazici H, Turkmen A, et al. Serum uric acid level is associated with cardiac hypertrophy in renal transplant recipients. Clin Transplant. 2011;25(3):368-74.
Boratyńska M, Karbowska A, Klinger M. The effect of hyperuricemia on endothelial biomarkers and renal function in kidney allograft recipients. Transplant Proc. 2010;42(10):4074-7.
Karbowska A, Boratynska M, Kusztal M, Klinger M. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant Proc. 2009;41(8):3052-5.
Min SI, Yun IJ, Kang JM, Park YJ, Min SK, Ahn C, et al. Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of long-term kidney transplant outcome. Nephrol Dial Transplant. 2009;24(8):2584-90.
Bandukwala F, Huang M, Prasad GV. Role of uric acid in post-renal transplantation hypertension. Transplant Proc. 2009;41(5):1634-6.
Zhang K, Gao B, Wang Y, Wang G, Wang W, Zhu Y, et al. Serum Uric Acid and Renal Transplantation Outcomes: At Least 3-Year Post-transplant Retrospective Multivariate Analysis. PLoS One. 2015;10(7):e0133834.
Kim KM, Kim SS, Yun S, Lee MS, Han DJ, Yang WS, et al. Uric acid contributes to glomerular filtration rate deterioration in renal transplantation. Nephron Clin Pract. 2011;118(2):c136-42.
Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Uric acid levels have no significant effect on renal function in adult renal transplant recipients: evidence from the symphony study. Clin J Am Soc Nephrol. 2009;4(10):1655-60.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155.
Bellomo G. Asymptomatic hyperuricemia following renal transplantation. World J Nephrol. 2015;4(3):324-9.
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24.
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47-56.
Reinders MK, Haagsma C, Jansen TL, Van Roon EN, Delsing J, Van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68(6):892-7.
Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-21.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-46.
Lee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, et al. Initiating allopurinol therapy: do we need to know the patient’s human leucocyte antigen status? Intern Med J. 2012;42(4):411-6.
Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76(16):1835-47.
Love BL, Barrons R, Veverka A, Snider KM. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy. 2010;30(6):594-608.
Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1111-6.
Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31(11):2503-18.
Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65-75.
Schumacher HR Jr, Becker MA, Lloyd E, Mac-Donald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-94.
Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-82.
Tadashi S, Masashi I, Taiga H, Yoko N, Kumiko M, Yushi H, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Drug Des Devel Ther. 2014;8:245-53.
Zürcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9(5):548-51.
Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64(3):876-84.
Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383-91.
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based, calcineurininhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377(9768):837-47.
Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-52.
Kamper AL, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation. 2001;72(4):671-4.
Goldman L, Schafer A. Cecil & Goldman Tratado de medicina interna. 24a ed. Barcelona: Elsevier, 2013.
Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64(21):2399-416.
Delaney V, Sumrani N, Daskalakis P, Hong JH, Sommer BG. Hyperuricemia and gout in renal allograft recipients. Transplant Proc. 1992;24(5):1773-4.
Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50(8):953-9.
Vázquez-Mellado J, García CG, Vázquez SG, Medrano G, Ornelas M, Alcocer L, et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol. 2004;10(3):105-9.
Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321(5):287-92.
Stamp L, Searle M, O’Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65(18):2593-611.
Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92(2):141-6.
Cohen MR. Proximal gout following renal transplantation. Arthritis Rheum. 1994;37(11):1709.
Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5):974-9.
Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-61.
Wluka AE, Ryan PF, Miller AM, Richardson M, Bergin PJ, Page JL, et al. Post-cardiac transplantation gout: incidence of therapeutic complications. J Heart Lung Transplant. 2000;19(10):951-6.
Pilmore HL, Faire B, Dittmer I. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. Transplantation. 2001;72(10):1703-5.
Jacobs F, Mamzer-Bruneel MF, Skhiri H, Thervet E, Legendre C, Kreis H. Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout. Transplantation. 1997;64(7):1087-8.
